1. Introduction {#sec1}
===============

In 2007, the International Federation of Clinical Chemistry (IFCC) clearly defined glycated hemoglobin A (HbA1c) as a stable adduct formed by glucose and the free amino group of the hemoglobin *β* chain-N-terminal proline \[[@B1]\]. In 2011, World Health Organization officially recommended HbA1c ≥ 6.5% as a diagnostic cutoff point for diabetes \[[@B2]\]. The American Diabetes Association (ADA) recommends that HbA1c should be measured in patients with newly developed diabetes, and it plays an important role in the monitoring of diabetes as an evaluation index to judge the effect of blood glucose control. Helicobacter pylori infection is now considered the most important cause of gastritis and peptic ulcer in humans. And studies have reported on the potential links between H. pylori infection and a variety of extra-gastroduodenal manifestations ischemic as heart disease, liver diseases, skin diseases, blood disorders, neurologic disorders, and others \[[@B3]\]. Christie et al. found serological evidence of H. pylori infection which was associated with an increased rate of incident diabetes in a Latino elderly cohort \[[@B4]\]. However, studies on the relationship between H. pylori infection and HbA1C in diabetic patients are inconsistent and sometimes contradictory. The finding of Bazmamoun et al. showed that there was no correlation between Helicobacter pylori infection and HbA1c levels \[[@B5]\]. Studies by Akın et al. found that HbA1c levels in Helicobacter pylori-positive patients were significantly higher than those in Helicobacter pylori-negative patients \[[@B6]\]. Due to these discrepancies, we performed a meta-analysis investigating the relationship between H. pylori infection and glycated hemoglobin A in patients with diabetes.

2. Methods {#sec2}
==========

2.1. Literature Search Strategy {#sec2.1}
-------------------------------

"Helicobacter pylori" and "glycated hemoglobin A" were jointly searched in PubMed database, the Embase database, and China National Knowledge Infrastructure (CNKI) as keywords for all relevant literature published before April 2019. Moreover, we also reviewed the reference not captured by our database search.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

The inclusion criteria were as follows: (1) observational studies; (2) studies are related to the relationship between H. pylori and diabetes, including case groups and control groups, and providing the exact sample size, the number of patients with H. pylori infection, and the mean and standard deviation of the level of HbA1c; (3) the diagnosis of diabetes was in agreement with international guidelines \[[@B7]\]; (4) H. pylori infection is judged by at least one diagnostic method; and (5) the studies are not directly related but with the abovementioned requirements.

2.3. Exclusion Criteria {#sec2.3}
-----------------------

The exclusion criteria were as follows: (1) case report and observational studies without control groups; (2) studies in which the data of the level of HbA1c were not available for either diabetes group or control group; (3) subset of a published article by the same authors or repeated published literature; (4) studies limited to animal; and (5) the data of literature are incomplete with little information, and the extraction of original data is not enough to calculate the statistics of this study.

2.4. Study Selection {#sec2.4}
--------------------

Two researchers independently screened the literature, extracted the data, and cross-checked. If the results were inconsistent, those would be discussed together or judged by a third senior researcher. This study used pre-established data extraction forms to extract data from the literature that will eventually be included in the meta-analysis. The excerpts included the first author, the year of publication, the study area, the diagnostic criteria for H. pylori infection, the sample size of the case and control groups, and the mean and standard deviation of HbA1c.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The data and the database were organized and checked carefully according to the requirements of the meta-analysis. RevMan 5.3 was used for statistical analysis, and weighted mean difference (WMD) with 95% CI was used for quantitative analysis of measurement data. *I*^2^ was used to quantitatively test the heterogeneity among different studies. If *I*^2^ ≤ 50%, the heterogeneity had no statistical significance, and fixed effects model was used to analyze it. On the contrary, if *I*^2^ \> 50% the heterogeneity had statistical significance, and random effects model was used to analyze. Moreover, subgroup analysis was carried out to explore the sources of heterogeneity according to the factors that might produce heterogeneity. To ensure the stability of the results of the meta-analysis, the sensitivity analysis (after the included studies removed one by one, the combined analysis was performed again, and the significant difference between the effect values before and after the combination was compared) was performed. The funnel plot, Egger\'s test, and fail-safe number were used to quantitatively evaluate the publication bias. *p* \< 0.05 was considered statistically significant, suggesting that publication bias is not excluded.

3. Results {#sec3}
==========

3.1. Study Selection and Characteristics {#sec3.1}
----------------------------------------

A total of 459 articles were initially searched by terms, and 35 studies eventually met the predetermined inclusion and exclusion criteria ([Figure 1](#fig1){ref-type="fig"}). The relevant literature was published from 2000 to 2018 ([Table 1](#tab1){ref-type="table"}). A total of 4,401 diabetic patients were included in the meta-analysis, including 1176 patients with type 1 diabetes, 2877 patients with type 2 diabetes, and 348 patients who were not typed. The included literature included 20 case-control studies involving 1970 patients with diabetes and 15 cross-sectional studies involving 2,431 people with diabetes.

3.2. Results of Meta-Analysis {#sec3.2}
-----------------------------

RevMan 5.3 was used to test the heterogeneity, *I*^2^ = 89%, *p* \< 0.001, so the random effects model was used to conduct a combined analysis. 35 studies (WMD = 0.50, 95% CI: 0.28-0.72, *p* \< 0.001) showed that there was a significant difference in the level of HbA1c between patients infected with H. pylori and that of noninfected patients. H. pylori infection was correlated with the increased level of HbA1c ([Figure 2](#fig2){ref-type="fig"}).

3.3. Subgroup Analysis {#sec3.3}
----------------------

In order to further increase the reliability of the study, the subtypes of diabetes mellitus, the design of the studies and different detection methods of H. pylori were analyzed, which were divided into three subgroups: type 1 diabetes mellitus and type 2 diabetes mellitus; cross-sectional studies and case-control studies; and biopsy and other detection methods. The results of the analysis are shown in Figures [3](#fig3){ref-type="fig"}[](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}. (1) In subgroup analysis by the type of diabetes, it is indicated that there is a significant correlation between H. pylori infection and increased HbA1c in type 1 diabetic patients (*I*^2^ = 74%, *p* \< 0.001, WMD = 0.46, 95% CI: 0.12-0.80) and in type 2 diabetes (*I*^2^ = 90%, *p* \< 0.001, WMD = 0.59, 95% CI: 0.28-0.90, *p* \< 0.001). (2) In subgroup analysis by design of studies, 15 of them were cross-sectional studies, of which 2217 were infected with H. pylori and 2184 were uninfected. 20 studies were case-control studies, of which 524 patients with H. pylori infection and 1046 patients without. A total of 35 studies were analyzed by meta-analysis. It is showed that H. pylori infection was associated with HbA1c in cross-sectional study (*I*^2^ = 89%, *p* \< 0.001, WMD = 0.42, 95% CI: 0.16-0.69, *p* ≤ 0.003) and in case-control study (*I*^2^ = 83%, *p* \< 0.001, WMD = 0.39, 95% CI: -0.14-0.64, *p* ≤ 0.003). (3) Gastric biopsy group and other detection methods group: biopsy was used in 6 studies and other detection methods were used in 29 studies, including serological detection and breath test. There was statistical significance in the biopsy group (*I*^2^ = 83%, *p* \< 0.001, WMD = 0.6, 95% CI: 0.11-1.09, *p* ≤ 0.03) and in other groups of test methods (*I*^2^ = 87%, *p* \< 0.001, WMD = 0.37, 95% CI: 0.17-0.56, *p* \< 0.001). It shows that H. pylori infection is correlated with the level of HbA1c whether in biopsy or other methods.

4. Publication Bias {#sec4}
===================

Egger\'s test (*p* \> 0.05) showed no significant publication bias. Funnel plot is basically symmetrical and has no publication bias ([Figure 6](#fig6){ref-type="fig"}). Fail-safe numbers, indicating the publication bias, are reported in [Table 2](#tab2){ref-type="table"}. The fail-safe numbers were all relatively large in the meta-analysis, suggesting that the results were reliable.

5. Discussion {#sec5}
=============

The quantitative data of this meta-analysis showed that the level of HbA1c in the H. pylori-infected group was significantly higher than that in the H. pylori-negative group, indicating that H. pylori infection and HbA1c were correlated in diabetes. Subgroup analysis revealed that (1) Helicobacter pylori infection was correlated with the level of HbA1c in type 1 diabetes mellitus and type 2 diabetes mellitus. (2) According to the type of studies, they were divided into two subgroups: case-control study and cross-sectional study. There was statistical significance in cross-sectional studies and case-control studies. (3) According to the diagnostic criteria of H. pylori infection, the H. pylori infection was correlated with the level of HbA1c in the gastric biopsy group. Similarly, the differences in other test groups were also statistically significant.

The results of this study are not completely consistent with the results of a meta-analysis of Dai et al. \[[@B41]\] in 2015. Their 11 studies showed that HbA1c of type 1 diabetic patients with H. pylori infection was significantly higher than that of type 1 diabetic patients without H. pylori infection (WMD = 0.35, 95% CI: 0.05-0.64; *p* ≤ 0.03). However, there was no significant difference in the levels of HbA1c between type 2 diabetes mellitus with and without H. pylori infection (WMD = 0.51, 95% CI: -0.63-1.65; *p* ≤ 0.38). According to the results of increasing sample size, both type 1 diabetes mellitus and type 2 diabetes mellitus patients infected with H. pylori have high levels of HbA1c and poor control of glycemic indices.

It is estimated that about 4.4 billion people worldwide were infected with H. pylori in 2015 \[[@B42]\], and it is estimated that diabetes will reach 552 million by 2020 \[[@B43]\]. Kato et al. have shown that H. pylori infection is associated with an increased risk of diabetes mellitus \[[@B44]\]. Refaeli et al. showed that the prevalence of metabolic syndrome in H. pylori-infected patients was higher than that in uninfected patients \[[@B45]\]. More and more data indicated that inflammation may play a role in the pathogenesis of type 2 diabetes, and the pathogenesis of type 2 diabetes can be regarded as an autoinflammatory disease \[[@B46]\]. Simultaneously, the inflammatory response caused by H. pylori has also been confirmed by researches \[[@B47], [@B48]\]. At the same time, studies have shown that eradication of H. pylori can improve glucose homeostasis in type 2 diabetes mellitus by reducing proinflammatory factors \[[@B49]\]. In addition, studies have shown that H. pylori can promote insulin resistance by inducing chronic inflammation and affecting insulin regulation of gastrointestinal hormones \[[@B50]\]. Gastritis caused by H. pylori may affect the secretion of gastric-related hormones, such as leptin and growth hormone-releasing hormone, as well as gastrin and somatostatin, which may affect the susceptibility to diabetes \[[@B51]\]. Studies have also described a positive correlation between H. pylori infection and impaired insulin secretion \[[@B52]\]. The results of Zhou et al. showed that H. pylori infection induced hepatic insulin resistance through c-Jun/miR-203/SOCS3 signaling pathway and provided possible implications for insulin resistance \[[@B53]\]. Although the mechanism of the association between H. pylori infection and diabetes is still unclear, more and more studies have shown that there is a potential link between them. Because of the large number of patients with the two diseases, if the causal relationship between them becomes clear, the impact will be great.

Meta-analysis is a secondary literature analysis based on previous research evidence. Therefore, there are limitations and biases in the analysis. Case-control studies are inevitably affected by selective bias. The results are not as reliable as prospective studies, and there are some limitations. Moreover, the results of this study are not grouped by population, region, and race. The limitation of this meta-analysis is that it does not consider other characteristics that may affect blood sugar control besides H. pylori infection, such as treatment status, age, gender, obesity index, or smoking status.

In conclusion, the results of this meta-analysis indicate that Helicobacter pylori infection is associated with increased glycosylated hemoglobin A, with a large sample size and a certain degree of confidence. Although some biases affect the accuracy of the results, it is still possible to provide new reference and guidance for eradication of H. pylori as a secondary prevention or treatment of diabetes. Proper screening for H. pylori infection and regular monitoring of blood glucose and HbA1c may be effective for early detection of blood glucose disorders and prevention of type 2 diabetes. Further research, especially longitudinal studies, is necessary to validate current results.

6. Conclusion {#sec6}
=============

This study conducted a meta-analysis of existing literature and concluded that H. pylori infection may increase the level of glycosylated hemoglobin A in diabetic patients, and the same conclusions were obtained in both type 1 diabetes and type 2 diabetes. The sample size included in this paper is large and has credibility, which can guide clinical work to a certain extent. In clinical practice, individualized prevention and treatment need to be closely combined with the actual situation of the patient.
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  Authors                                 Year   Country        Type        HP+            HP−                  
  --------------------------------------- ------ -------------- ----------- -------------- ----- -------------- -----
  Chobot et al. \[[@B8]\]                 2014   Poland         T1DM        7.8 ± 1.42     17    7.60 ± 1.66    132
  Fernandini-Paredes et al. \[[@B9]\]     2008   Peru           T2DM        7.6 ± 0.23     49    7.25 ± 0.49    26
  Hamed et al. \[[@B10]\]                 2008   Egypt          T1DM/T2DM   8.1 ± 0.8      68    8.3 ± 0.1      6
  Candelli et al. \[[@B11]\]              2004   Rome           T1DM        8.2 ± 1.06     29    8.4 ± 1.7      29
  Yingjian \[[@B12]\]                     2018   China          T2DM        8.7 ± 1.45     45    6.77 ± 1.52    49
  Qing et al. \[[@B13]\]                  2018   China          T2DM        8.2 ± 0.77     51    7.10 ± 0.55    59
  Ziyue et al. \[[@B14]\]                 2017   China          T2DM        8.6 ± 1.84     85    7.70 ± 0.75    51
  Chunying et al. \[[@B15]\]              2016   China          T2DM        8.4 ± 1.68     62    8.53 ± 1.96    69
  Licheng et al. \[[@B16]\]               2016   China          T2DM        7.7 ± 1.34     106   6.24 ± 0.58    64
  Li \[[@B17]\]                           2016   China          T2DM        8.4 ± 2.06     112   8.01 ± 2.01    68
  Zhili et al. \[[@B18]\]                 2014   China          T2DM        9.0 ± 0.89     48    8.02 ± 0.23    25
  Yi et al. \[[@B19]\]                    2011   China          T2DM        9.21 ± 2.4     43    9.34 ± 2.1     22
  Candelli et al. \[[@B20]\]              2003   Rome           T1DM        8.3 ± 1.1      34    8.2 ± 1.5      87
  Fayed et al. \[[@B21]\]                 2014   Egypt          T1DM        7.4 ± 1.6      40    7.9 ± 1.3      13
  Vafaeimanesh et al. \[[@B22]\]          2016   Iran           T1DM/T2DM   8.1 ± 1.67     139   8.08 ± 1.32    72
  Nasif et al. \[[@B23]\]                 2016   Saudi Arabia   T2DM        6.9 ± 0.69     33    7.30 ± 0.55    17
  Anandani et al. \[[@B24]\]              2014   Indonesia      T2DM        9.52 + 1.12    5     9.08 + 1.22    25
  Toporowska-Kowalska et al. \[[@B25]\]   2007   Poland         T1DM        7.87 ± 1.51    48    7.17 ± 1.46    150
  Bazmamoun et al. \[[@B6]\]              2016   Iran           T1DM        8 ± 0.65       48    7.90 ± 0.40    32
  Huang et al. \[[@B26]\]                 2015   China          T2DM        8.34 ± 2.02    195   8.47 ± 2.04    220
  Demir et al. \[[@B27]\]                 2008   Turkey         T2DM        7.9 ± 1.8      87    8.7 ± 7.1      54
  Arslan et al. \[[@B28]\]                2000   Turkey         T1DM        11.08 ± 3.17   49    10.32 ± 2.63   39
  Colombo et al. \[[@B29]\]               2002   Italy          T1DM        8.16 ± 1.7     41    7.8 ± 1.6      97
  Gulcelik et al. \[[@B30]\]              2005   Turkey         T2DM        8.2 ± 1.4      59    7.9 ± 2.2      19
  Zekry et al. \[[@B31]\]                 2013   Egypt          T1DM        7.75 ± 1.67    24    5.72 ± 1.2     36
  Ko et al. \[[@B32]\]                    2001   China          T2DM        8.09 ± 2.11    32    8.42 ± 2.37    31
  Jones et al. \[[@B33]\]                 2002   Australia      DM          8.8 ± 0.4      15    8.6 ± 0.2      48
  Candelli et al. \[[@B34]\]              2012   Italy          T1DM        8.8 ± 0.8      17    8.4 ± 0.7      52
  Zhou et al. \[[@B35]\]                  2012   China          T2DM        8.45 ± 2.46    84    8.18 ± 2.13    96
  El-Eshmawy et al. \[[@B36]\]            2011   Egypt          T1DM        8.3 ± 1.58     128   6.8 ± 2.3      34
  Senmaru et al. \[[@B37]\]               2013   Japan          T2DM        7.3 ± 1.0      146   7.4 ± 1.2      187
  Tanrivedi \[[@B38]\]                    2011   Turkey         T2DM        6.9 ± 1.2      53    6.1 ± 1.4      40
  Peng et al. \[[@B39]\]                  2013   China          T2DM        9.53 ± 1.96    43    7.08 ± 1.53    42
  Akın. et al. \[[@B6]\]                  2014   Turkey         T2DM        8.0 ± 2.1      159   6.9 ± 1.2      156
  El Hadidy et al. \[[@B40]\]             2009   Saudi Arabia   T2DM        9.2 ± 2.1      23    8.92 ± 2.1     37

###### 

Fail-safe numbers of all groups for the studies.

                                      Number of studies   Fail-safe number   
  ----------------------------------- ------------------- ------------------ ---------
  All diabetic patients               35                  1799.584           873.894
  Subgroup of type 1 diabetes         11                  101.251            44.612
  Subgroup of type 2 diabetes         21                  936.340            453.288
  Subgroup of case-control            20                  491.393            233.356
  Subgroup of cross-sectional study   15                  393.769            187.513
  Subgroup of biopsy                  6                   78.977             36.010
  Subgroup of other methods           29                  1100.883           530.770
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